Biomarker evaluation as the cardiotoxic evaluation index in the molecular target drug for breast cancer treatment

Biomarker evaluation as the cardiotoxic evaluation index in the molecular target drug for breast cancer treatment - Biomarker evaluation as the cardiotoxic evaluation index in the molecular target drug for breast cancer treatment

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000020690

Enrollment

100

Registered

2016-01-21

Start date

2014-11-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HER2-positive breast cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients with breast cancer that treatment with antiHER2 medicine is planned 2)By an explanation document, the agreements from a patient to a trial entry are provided

Exclusion criteria

Exclusion criteria: 1)The patient who withdrew an agreement 2)Examination participation of the patients is taken as inappropriate by the medical attendant

Design outcomes

Primary

Measure	Time frame
The cardiotoxicity that was defined according to a standard of CREC(the Cardiac Review and Evaluation Committee of Trastuzumab-associated cardiotoxicity)	—

Countries

Japan

Contacts

Public ContactYoshinori Ito

Cancer Institute Hospital of Japanese Foundation for Cancer Research Breast Oncology

yito@jfcr.or.jp03-3520-0111

Outcome results